#USA #Epidermolysis Bullosa #Paradigm Therapeutics #SD-101 #Mount Pleasant, SC

Paradigm Therapeutics Launches Significant Phase 3 Study

Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to addressing significant unmet medical needs, has recently made strides towards developing innovative therapies for rare diseases. The company announced an important milestone: the first patient has been enrolled in a pivotal Phase 3 clinical trial for its groundbreaking topical formulation, SD-101 (also known as Zorblesia™). This study focuses on the treatment of Epidermolysis Bullosa (EB), a debilitating genetic skin disorder.

EB is characterized by exceptionally fragile skin that blisters and tears easily, often presenting at birth or in early childhood. Patients face chronic pain, wounds, and a range of life-altering complications, dramatically affecting their quality of life. Current therapeutic options available are limited, underscoring the importance of Paradigm's efforts in developing SD-101.

Study Overview

The Phase 3 trial, designated as the SD-007 study, is a multicenter, prospective, randomized, double-blinded, placebo-controlled trial designed to assess the efficacy and safety of SD-101 in treating EB. The study will include a diverse group of approximately 80 patients aged between 28 days and 12 years across 17 clinical sites in 14 countries across North America, South America, Europe, Asia, and Australia.

Participants will be assigned to apply either SD-101 or a placebo cream daily for two months, allowing researchers to monitor wound healing, changes in skin area affected by lesions, and improvements regarding itchiness and discomfort.

“The impact of EB on individuals and their families can be profound,” said Robert Ryan, Ph.D., the President and CEO of Paradigm Therapeutics. “SD-101 represents a potential breakthrough in the treatment landscape, aiming to address the widespread skin abnormalities associated with EB simplex, recessive dystrophic EB, and junctional EB. We’re committed to advancing this drug through the necessary clinical trials and toward regulatory approval.”

Previous Clinical Studies

Prior to this Phase 3 study, Paradigm Therapeutics successfully conducted Phase 2 trials, showcasing that SD-101 could significantly promote wound healing on a large scale. The cream has been well tolerated among pediatric and adult patients, suggesting a favorable safety profile. The achievement of the SD-007 study marks a vital step in translating clinical research into potential patient care improvements.

A Call to Action

The SD-007 study also provides the groundwork for further evaluations through a subsequent study (SD-008) for participants who complete the initial trial. This offers a continuum of care for those in need of long-term treatment solutions.

Dr. Fred Eshelman of Eshelman Ventures, a prominent supporter of Paradigm, noted, “Our investment reflects our belief in Paradigm’s mission to deliver innovative solutions for treating EB. The relentless challenges faced by patients emphasize the urgent need for enhanced treatment options.”

Conclusion

As Paradigm Therapeutics forges ahead with its clinical trials and engages with potential partners for global development, the hope for a transformative solution to the challenges posed by EB continues to grow. SD-101 has the potential not only to alleviate pain but also to vastly improve the overall quality of life for patients battling this rare skin condition. Keep an eye out for updates as this promising narrative unfolds in the ongoing fight against Epidermolysis Bullosa.